@mbelshazly's Threads
1/ Today, at #ESCcongress2019 DAPA-HF trial showed amazing results. I love the complex story behind developing these novel #diabetes drugs and their impact on CVD so I'm going to share it in this tweetorial #cardiotwitter
2/ First let me start by sharing DAPA-HF results. Basically, in pts with HFrEF, Dapagliflozin (SGLT-2i) arm had 26% reduction in primary outcome & 18% reduction in CV death REGARDLESS of #diabetes. Link to tweet w/results thx to @rladeiraslopes
3/ Pre 2008, the FDA approved anti-diabetic medications based on their ability to reduce biomarkers, glucose and A1C, without the need for clinical outcome trials. Basically, anything that lowers A1c in diabetics got approved
